Soluble Endoglin Inhibits Platelet Aggregation via Integrin Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for thrombotic disorders, particularly in hereditary hemorrhagic telangiectasia (HHT), face challenges due to high bleeding risks associated with antithrombotic therapies like eptifibatide and abciximab, and there is a need for safer alternative approaches to manage both bleeding and thrombotic complications.

Innovation Solution

Soluble endoglin (sEng) is used to inhibit platelet aggregation and thrombus formation by binding to the αIIbβ3 integrin, thereby reducing thrombus size and stability, offering a potential antithrombotic therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antithrombotic therapy is used to treat thrombotic disorders in HHT patients, then thrombus formation is reduced, but bleeding risk increases

Engineering Contradiction:

Improvethrombus formation controlVSAvoidbleeding risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses soluble endoglin (sEng) as an intermediary substance that mediates between platelet activation and fibrinogen binding. sEng binds to the αIIbβ3 integrin on platelets, preventing fibrinogen from binding to the same integrin, thereby inhibiting platelet aggregation and thrombus formation without causing excessive bleeding. This intermediary mechanism allows selective modulation of thrombus formation while maintaining hemostatic balance.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameter of integrin αIIbβ3 availability by introducing sEng, which alters the binding dynamics between platelets and fibrinogen. By modifying the concentration and binding affinity parameters of sEng to integrin αIIbβ3, the patent achieves control over thrombus formation while avoiding excessive bleeding tendencies.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If platelet integrins are activated to treat thrombus formation, then thrombus dissolution is improved, but mortality risk increases

Engineering Contradiction:

Improvethrombus dissolutionVSAvoidmortality risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs soluble endoglin as a mediator that interferes with the direct interaction between fibrinogen and platelet integrins. By binding to integrin αIIbβ3, sEng prevents fibrinogen-mediated platelet aggregation and thrombus stabilization, achieving thrombus dissolution without the severe pro-thrombotic effects and mortality risks associated with direct integrin activators like eptifibatide and abciximab.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the natural binding affinity of integrin αIIbβ3 for fibrinogen into a therapeutic opportunity. Instead of blocking integrin activation entirely (which causes mortality risks), sEng selectively interferes with fibrinogen binding to activated integrins, promoting thrombus dissolution while maintaining physiological hemostasis and avoiding excessive bleeding or mortality.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If oral integrin-activating drugs are used, then thrombus formation is inhibited, but mortality increases due to unexpected side effects

Engineering Contradiction:

Improvethrombus formation inhibitionVSAvoidmortality from side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses soluble endoglin as a safe intermediary that naturally interferes with platelet-fibrinogen interactions. Unlike synthetic oral integrin activators that directly stimulate integrins and cause severe side effects and mortality, sEng works as a physiological mediator that modulates the binding dynamics between platelets and fibrinogen, achieving thrombus inhibition without the dangerous side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs soluble endoglin, a naturally occurring protein that is rapidly cleared from the circulation, as a temporary and safe therapeutic agent. This short-lived intermediary provides acute thrombus inhibition when needed, then naturally dissipates without causing prolonged pro-thrombotic effects or mortality, unlike persistent oral integrin activators.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

sEng supplementation slows thrombus formation, reduces platelet aggregation, and impairs thrombus retraction, providing a safer therapeutic option for managing thrombotic disorders while minimizing bleeding risks.

Implementation Method 1

sEng inhibition of platelet aggregation and thrombus formation by binding to the αIIbβ3 integrin

Methodology Applied

Scientific EffectProtein binding: Chemical Bonding

Data Source

PatentUS20250099540A1Methods and pharmaceutical composition for treating thrombotic disorders

Publication Date: 2025.03.27 INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)

AI summary

The present invention relates to a method and compositions comprising soluble Endoglin. for the treatment of thrombotic diseases, and more particularly for the treatment of stroke.